A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

October 23, 2017

Study Completion Date

October 25, 2019

Conditions
Melanoma
Interventions
BIOLOGICAL

Nivolumab

-Specified dose on specified days

BIOLOGICAL

Ipilimumab

-Specified dose on specified days

Trial Locations (16)

10137

Azienda Ospedaliera Citta della Salute e della Scienza, Torino

13385

Hopital De La Timone, Marseille

16128

Istituto Nazionale Per La Ricerca Sul Cancro - Oncologia Med, Genova

20141

Istituto Europeo Di Oncologia, Milan

28007

Local Institution, Madrid

37044

Hopital Trousseau - Chru Tours, Tours

41071

Local Institution, Seville

44093

Local Institution, Nantes

47014

Istituto Scientifico Romagnolo Per Lo Studio E Cura Tumori, Meldola (FC)

69373

Local Institution, Lyon

75475

Hopital Saint Louis, Paris

75679

Local Institution, Paris

Unknown

Melanoma Institute Australia, North Sydney

Greenslopes Private Hospital, Greenslopes

Cabrini Hospital, Malvern

08036

Local Institution, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02905266 - A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma | Biotech Hunter | Biotech Hunter